The benefit of the b 1 -adrenergic receptor (b 1 -AR) agonist dobutamine for treatment of acute heart failure in peripartum cardiomyopathy (PPCM) is controversial. Cardiac STAT3 expression is reduced in PPCM patients. Mice carrying a cardiomyocyte-restricted deletion of STAT3 (CKO) develop PPCM. We hypothesized that STAT3-dependent signalling networks may influence the response to b-AR agonist treatment in PPCM patients and analysed this hypothesis in CKO mice.
Introduction
Peripartum cardiomyopathy (PPCM) is a non-familial cardiomyopathy presenting with heart failure (HF) secondary to left ventricular (LV) systolic dysfunction towards the end of pregnancy or in the months following delivery, when no other cause of HF is found. 1, 2 Onset of the disease is often sudden and in severe cases associated with cardiogenic shock. However, partial or full recovery is frequently possible. 1, 2 The benefit of dobutamine treatment in PPCM patients with acute HF is controversial and may be associated with adverse outcome. 2 Here, we evaluated clinical data sets from the German PPCM registry and observed that all PPCM patients treated with dobutamine required either cardiac transplantation or LV assist devices (LVAD), while in 95% of patients not receiving dobutamine despite similar initial impairment of LV function, cardiac function recovered without the need of cardiac support or transplantation. Reduced cardiac STAT3 expression was observed in PPCM patients and may play a causal role in disease pathogenesis since mice with a cardiomyocyte-specific deletion of Stat3 (aMHC-Cre tg/+ ; Stat3 fl/fl ; CKO) develop PPCM. 3 During the peripartum phase, STAT3 protects the maternal heart from excessive oxidative stress and the subsequent generation of a disease-promoting angiostatic fragment of the nursing hormone prolactin (16 kDa-PRL), which compromises the cardiac microvasculature. 3, 4 Here, we hypothesized that STAT3 may also protect the maternal heart from adverse effects caused by b 1 -adrenergic receptor (b 1 -AR) activation. Indeed, the b-AR agonist isoproterenol (Iso) caused HF and high mortality in postpartum as well as nulli-pari CKO mice mainly by inducing metabolic deficits through impairing fatty acid and glucose uptake. The latter was governed by a disturbed STAT3-dependent signalling network involving microRNA-199a-5p (miR-199a) and microRNA-7a-5p (miR-7a), insulin/glucose transporter-4 (GLUT4), and neuregulin (NRG)/ErbB signalling. The resulting cardiac energy depletion impairs the regeneration of mitochondrial pyridine nucleotides, which decreased ATP production and increased emission of reactive oxygen species (ROS) causing functional impairment and cardiomyocyte necrosis and with this irreversible HF. This could be attenuated by the b 1 -AR blocker metoprolol or the glucoseuptake-promoting drug perhexiline 5 that is currently tested in clinical studies. 6 Therefore, diminished cardiac STAT3 expression may render PPCM patients more vulnerable to b 1 -AR agonists-induced cardiac damage and HF progression.
Methods
Expanded methods are available in the Supplementary material online.
Results
Dobutamine treatment is associated with an adverse outcome in peripartum cardiomyopathy patients with severe heart failure Twenty-seven PPCM patients were selected from the German PPCM registry 7 according to a baseline LV ejection fraction (LVEF) ≤25% and the presence of clinical follow-up data (9 + 4 months). During acute HF, 7 of these patients were treated with dobutamine (Dob-group) while 20 did not obtain dobutamine (no-Dob-group). The decision to use dobutamine was left to the discretion of the treating physicians. The clinical presentation at diagnosis was similar between both groups, while age, gravida, and parity were higher in the no-Dob-group compared with the Dob-group (Table 1) . Patients in the no-Dob-group were more frequently treated with a b-blocker (n ¼ 19 out of 20) compared with the Dob-group (n ¼ 4 out of 7, P ¼ 0.042), while the proportion of patients receiving an angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker or bromocriptine was similar ( Table 1) . All seven patients in the Dob-group experienced an adverse outcome, i.e. LVAD implantation (n ¼ 3) or heart transplantation (n ¼ 4) and/or subsequent death (n ¼ 1). In contrast, 95% of the no-Dob-group improved LVEF (baseline, 18 + 5%; follow-up, 46 + 11%; P , 0.0001), while only one patient (5%) underwent heart transplantation (P , 0.0001 vs. Dob-group; two-sided Fisher's exact test).
Chronic b 1 -adrenergic receptor stimulation induces heart failure in postpartum mice with cardiomyocytes-specific STAT3 deletion
To investigate the role of STAT3 during b-AR stimulation, CKO and wild-type (WT) female mice were randomized after one pregnancy to obtain osmotic minipumps containing either NaCl, Iso (30 mg/kg/ day) or Iso and the prolactin blocker bromocriptine. Cardiac function was moderately decreased in NaCl-treated CKO mice, while Iso induced severe HF ( Figure 1A and B) and increased mortality, which could not be prevented by bromocriptine (mortality: NaCl 0/7, Iso 2/7, Iso + bromocriptine 5/9). Iso or Iso + bromocriptine treatment had no adverse effect in postpartum WT mice, which all survived and maintained cardiac function ( Figure 1A and B) .
Clinical summary † The benefit of the b 1 -adrenergic receptor (b 1 -AR) agonist dobutamine for treatment of acute heart failure in peripartum cardiomyopathy (PPCM) is controversial. Cardiac STAT3 expression is reduced in PPCM patients, and mice with a cardiomyocyte-restricted deletion of STAT3 develop PPCM. † Data from the German PPCM registry show that dobutamine treatment in patients with severe PPCM was associated with an adverse outcome (heart transplantation or left ventricular assist device implantation) while almost all patients not receiving dobutamine recovered. † b 1 -AR stimulation with isoproterenol in mice lacking cardiomyocyte STAT3 induced severe cardiac dysfunction and high mortality. In STAT3-deficient cardiomyocytes b 1 -AR stimulation impaired glucose uptake and subsequently induced energy depletion, oxidative stress, dysfunction, and death. † Our study provides novel insights how dobutamine in the pathophysiology of PPCM may induce irreversible heart failure progression and suggests how the glucose-uptake-enhancing drug perhexiline could help to prevent this.
Chronic Iso stimulation induces heart failure in non-pregnant STAT3-deficient mice mainly by b 1 -adrenergic receptor activation
To investigate whether STAT3 may be important for cardioprotection during b-AR treatment independent of pregnancy and pregnancy hormones, male CKO mice were subjected to Iso treatment (10-30 mg/kg/day) for 2 weeks, which led to a dose-dependent increase in mortality compared with WT siblings ( Figure 1C) . In CKO mice, Iso treatment induced LV dysfunction and increased LV dilatation with increased heart/body weight ratios ( Table 2 ; Supplementary material online, Figure S1 ) and cardiomyocyte lengths (CML: +33 + 14%, *P ¼ 0.0001 vs. CKO NaCl; *P indicates two-way AN-OVA) with no significant increase in cardiomyocyte cross-sectional area (CSA: +32 + 28%, *P ¼ 0.0861 vs. CKO NaCl). In WT and heterozygous (aMHC-Cre tg/+ ; Stat3 fl/+ ) mice LV function remained compensated ( Table 2 ; Supplementary material online, Figures S1 and S2). Iso-treated WT mice displayed ventricular hypertrophy (Supplementary material online, Figure S1 ) and increased CSA (+50 + 38%, *P ¼ 0.0101 vs. WT NaCl) with no change in CML (+9 + 12%, *P ¼ 0.3317 vs. WT NaCl). Blood pressure was similar in both genotypes (Supplementary material online, Figure S1 ). Similar to males, nulli-pari female CKOs developed LV dysfunction in response to Iso (fractional shortening: CKO, 22 + 6%; WT, 44 + 5%; # P , 0.0001; # P indicates two-tailed Student's t-test). The b 1 -selective blocker metoprolol largely attenuated Iso-induced adverse effects in CKO mice, while bromocriptine had no effect ( Table 2) . While Iso stimulation enhanced phosphorylation of troponin I (TnI) at the protein kinase A (PKA) and C (PKC) sites similarly in CKO and WT mice ( Figure 1D and E), a more pronounced increase in cardiac fibrosis, cardiomyocyte necrosis, and inflammation and higher expression of atrial and brain natriuretic peptides (BNP) were observed in CKO compared with WT mice (Figure 1F -K; Supplementary material online, Figure S1 ). Figure S3 ), although mitochondrial STAT3 protein content of CKO mice was decreased to a similar extent as in LV tissue ( Figure 2J ). In mitochondria, the Krebs cycle produces the pyridine nucleotides NADH and FADH 2 that fuel the electron transport chain (ETC) to produce ATP, and NADPH to regenerate the antioxidative capacity. In isolated cardiomyocytes of untreated mice, acute Iso stimulation (30 nM) combined with an increase of stimulation frequency from 0.5 to 5 Hz (simulating a physiological workload transition 8 ) induced an initial oxidation with subsequent recovery of NAD(P)H/NAD(P) + and FADH 2 /FAD redox states in both genotypes ( Figure 3A) . Accordingly, the ratio of NADPH/FAD (indexing b-AR agonist treatment in PPCM patients gross mitochondrial pyridine nucleotide redox state) and mitochondrial ROS emission were similar in both genotypes ( Figure 3C and E). After 24 h in vivo Iso treatment of WT and CKO mice, pyridine nucleotide redox pools were substantially oxidized in cardiomyocytes from either genotype ( Figure 3B ). The physiological workload transition induced continuous recovery of pyridine nucleotides redox states in WT, starting at the onset of the Iso effect after 30 s, but not in CKO cardiomyocytes ( Figure 3B and D) . This was associated with an increase in ROS production in CKO vs. WT cardiomyocytes, again starting at the onset of the Iso effect after 30 s ( Figure 3F ).
Chronic b 1 -adrenergic receptor stimulation impairs substrate utilization in CKO mice
The depletion of mitochondrial pyridine nucleotides during workload transitions pointed to impaired metabolic activity. Serum levels of free fatty acids (FFA) and cardiac FFA uptake, measured by PET in vivo using the palmitate analogue 14(R,S)- 9 were similar at baseline and displayed a comparable decrease after Iso treatment associated with a similar reduction in the cardiac triglyceride content in both genotypes (Figure 4A-C; Supplementary material online, Figure S4 ). Blood glucose levels were similar at baseline and slightly reduced by Iso stimulation in both genotypes ( Figure 4D ). To rule out any contribution by inflammatory cells or fibroblasts (known for high glucose uptake), isolated cardiomyocytes from WT and CKO mice (untreated or after 24 h in vivo Iso treatment) were used. Baseline and insulin-induced glucose uptake (assayed by Pharmacological modulation of glucose uptake impacts on cardiac function and survival of CKO and wild-type mice exposed to chronic b 1 -adrenergic receptor stimulation
Baseline and Insulin-induced glucose uptake in cardiomyocytes is mainly mediated by GLUT4. Iso treatment decreased the expression and cardiomyocyte membrane localization of GLUT4 in LVs from CKO compared with WT mice, while GLUT1 was not affected ( Figure 4H-J) . Etomoxir, known to improve glycolysis in part by enhancing GLUT4 activity, 10 increased membrane localization of GLUT4 in Iso-stimulated CKO mice, which was associated with improved survival and cardiac function ( Figure 4J-L) . Also perhexiline enhances GLUT4-mediated glucose uptake 5 and improved survival and cardiac function in Iso-stimulated CKO mice (Supplementary material online, Figure S4 ). Perhexiline increased pyruvate levels in LV tissue of Iso-stimulated CKO mice (Supplementary material online, Figure S4 ). Conversely, impairing glycolysis with 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one, a small-molecule inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, 11 provoked high mortality and cardiac dysfunction in Iso-treated WT mice (Supplementary material online, Figure S4 ). b-AR agonist treatment in PPCM patients expression were reduced in CKO compared with WT mice at baseline and further decreased after Iso treatment ( Figure 5A and B). ErbB4 mRNA was also reduced in isolated CKO cardiomyocytes (249 + 9%, # P ¼ 0.0109 vs. WT). ErbB2, which requires heterodimerization with ErbB4 for activation, 6 was up-regulated in Isostimulated CKO LVs ( Figure 5A and C ) . The 'a disintegrin and Figure 3 Mitochondrial oxidation and reactive oxygen species production in cardiomyocytes from Iso-treated CKO and wild-type mice.
Isolated cardiomyocytes from untreated or Iso-treated (24 h) mice were electrically stimulated (0.5 Hz) and then exposed to Iso (30 nM) and increased stimulation frequency of 5 Hz for 3 min. (A and B) Auto-fluorescence of nicotinamide adenine dinucleotide phosphate (blue traces) and flavin adenine dinucleotide (magenta traces), (C and D) the ratio of nicotinamide adenine dinucleotide phosphate/flavin adenine dinucleotide, and (E and F ) mitochondrial . O 2 2 formation indexed by MitoSOX. n ¼ 8 -43; data are means + SD. # P , 0.05 CKO vs. wild type, two-way ANOVA; *P , 0.05, **P , 0.01, ***P , 0.001, and ****P , 0.0001 wild type vs. CKO Bonferroni post-test of two-way ANOVA.
b-AR agonist treatment in PPCM patients in neonatal rat cardiomyocytes with adenoviral miR-199a-OE compared with control and (N ) in neonatal rat cardiomyocytes with miR-7a-OE compared with control. All data are mean + SD. P-values were computed by two-way ANOVA and Bonferroni post hoc test (B, C, E, G, and H ) or by two-tailed Student's t-test (I and J ). Experiments in neonatal rat cardiomyocytes were performed in at least three independent cell isolations in triplicates.
b-AR agonist treatment in PPCM patients metalloprotease' (ADAM)17, which transactivates ErbB receptor signalling by shedding NRG1 from the cell surface, 14 displayed increased activation upon Iso treatment in WT and CKO LVs indicated by phosphorylation at threonine 735 15 ( Figure 5D and E).
ErbB4 knockdown by siRNA in neonatal rat cardiomyocytes (NRCM) (mRNA: 270 + 3% vs. control, # P ¼ 0.0007) blunted NRG1-, but not insulin-induced glucose uptake and reduced pyruvate content and metabolic activity ( Figure 5F-J) .
Inhibition of ErbB4 signalling with AST-1306 (80 mg/kg/day) had no effect on LV function and survival in control WT mice [LVFS (7 days): DMSO control, 41 + 8%, n ¼ 8 vs. DMSO/AST, 38 + 7%, n ¼ 7, *P . 0.9999] but increased mortality and LV dysfunction when combined with Iso treatment [LVFS (7 days): DMSO/Iso, 30 + 7%, n ¼ 8 vs. DMSO/AST/Iso, 15 + 13%, n ¼ 4, *P ¼ 0.0013; 2 of 6 DMSO/AST/Iso-stimulated mice died within 7 days].
microRNA-199a and microRNA-7a are involved in STAT3-dependent regulation of glucose uptake in the heart Since Iso did not regulate STAT3 activation (phosphorylation of tyrosine-705 or serine-727) in NRCM directly (data not shown), we evaluated whether miR-199a, which is suppressed by STAT3, 16 would target ErbB4 and/or GLUT4. In NRCM, miR-199a overexpression decreased while miR-199a reduction increased ErbB4 protein levels ( Figure 5K ). An anti-Argonaute ribonucleoprotein immunoprecipitation (RIP) assay confirmed direct regulation of ErbB4 by miR-199a (Supplementary material online, Results). MiR-199a had no effect on GLUT4 ( Figure 5M ). In silico analyses using TargetScan and RNA22 identified GLUT4 as a target of miR-7a in human, rat, and/or mouse. MiR-7a expression was similar at baseline in both genotypes (*P . 0.9999) but increased in CKO compared with WT after Iso treatment (1.8-fold after 3 days, *P ¼ 0.0003). MiR-7a overexpression did not alter ErbB4 but decreased GLUT4 protein levels (miR-7a-KD: 236 + 12%, # P ¼ 0.0208, Figure 5L and N).
Proof-of-concept analyses in left ventricular tissue from peripartum cardiomyopathy patients
Analyses in LV tissue from three PPCM patients of the Dob-group revealed reduced STAT3 protein, triglycerides, glucose, and lactate and increased miR-199 levels compared with non-failing LV tissue ( Figure 6A-F) .
There is evidence that hyperosmolar conditions could be associated with the development of PPCM. 17 Hyperosmolar conditions reduce STAT3 expression, 18 which we observed also in NRCM (Supplementary material online, Figure S5 ).
Discussion
Our study suggests that b 1 -AR stimulation in PPCM patients with acute HF is associated with adverse outcome, since in the German registry, 7 all PPCM patients treated with dobutamine needed either heart transplantation or an LVAD while almost all PPCM patients in comparably critical conditions but without dobutamine treatment recovered. A possible explanation why dobutamine may promote cardiac damage and HF progression could be the frequently observed low cardiac STAT3 expression in PPCM patients, 3 also confirmed here in some patients of the Dob-group. Indeed, the b-AR agonist Iso worsened HF in our experimental model for PPCM, i.e. postpartum CKO mice. This is independent from the cleaved 16 kDa-PRL, since HF could not be prevented by bromocriptine. Iso induced HF and high mortality in non-pregnant CKO mice, which could be attenuated by the b 1 -AR blocker metoprolol, indicating that STAT3 deficiency alone is sufficient for b 1 -AR-activation-induced terminal HF. One possible mechanism for reduced cardiac STAT3 expression in PPCM could be hyperosmolar stress, which decreases STAT3 in cardiomyocytes. Indeed, delivery itself, in particular when associated with substantial bleeding, produces hypovolemic and therefore hyperosmolar conditions. Furthermore, an ethnic tradition in Nigeria is to treat postpartum women with a high-salt diet, which is likely to generate hyperosmolarity. These women have the highest incidence of PPCM (1:100). 17 Additional mechanisms may involve previous anthracyline treatment that decreases cardiomyocyte STAT3 19 and that is a risk factor for PPCM. 7, 20 The link between STAT3 deficiency and toxic effects of b 1 -AR stimulation involves metabolic impairments. Iso depletes serum FFA, cardiac FFA uptake, and triglycerides as previously shown in rats 21 and confirmed in Iso-treated WT and CKO mice. As a consequence, glycolysis becomes the predominant metabolic pathway as confirmed by the observation that attenuating glycolysis during Iso stimulation caused cardiac dysfunction and high mortality in WT mice while improving glucose uptake by etomoxir or perhexiline 5, 10 improved cardiac function and survival in Iso-treated CKO mice. The glycolytic products lactate and pyruvate were reduced in STAT3-deficient cardiomyocytes from Iso-treated CKO mice as the consequence of impaired glucose uptake and possibly by additional impairment in rate limiting glycolytic enzymes. Subsequently, the Krebs cycle-mediated regeneration of the mitochondrial pyridine pool (NADH, NADPH, and FADH 2 ) that fuels the ETC for ATP production was lower in STAT3-deficient cardiomyocytes from Iso-treated CKO mice thereby explaining their lower cardiac energy status and possibly decreased cardiac function. The Krebs cycle also regenerates NADPH, which is required to detoxify ROS. 22, 23 Therefore, the impaired NADPH regeneration in STAT3-deficient cardiomyocytes was associated with increased mitochondrial ROS formation potentially underlying the induction of necrosis and cardiac damage 23 in Iso-stimulated CKO mice. Thus, STAT3 is needed to maintain glucose uptake and subsequent metabolic integrity during b 1 -AR activation, which prevents cardiac dysfunction and damage. We could show that STAT3 is required to maintain GLUT4-mediated glucose uptake in cardiomyocytes during Iso stimulation. The role of STAT3 hereby is to suppress Iso-induced up-regulation of miR-7a, a microRNA that targets GLUT4 because (i) reduction of GLUT4 protein was not paralleled by a similar decrease in mRNA, (ii) overexpression of miR-7a reduced GLUT4 protein in cardiomyocytes, and (iii) miR-7a is up-regulated in Iso-stimulated CKO compared with WT mice. Since GLUT4 is also regulated by lysosomal degradation, 24, 25 additional mechanisms such as impaired GLUT4 recycling and increased degradation may also contribute to the rapid decline of GLUT4 protein in Iso-treated CKO mice and will be evaluated in future studies.
We discovered that a regulatory network involving STAT3, miR-199a, and ErbB4 is important for cardiomyocyte glucose uptake at baseline and during Iso stimulation since (i) NRG1-induced glucose uptake is impaired in control and Iso-treated CKO cardiomyocytes, (ii) pharmacological blockade of ErbB4 by AST-1306 caused HF and increased mortality in Iso-stimulated WT mice, and (iii) Iso activates ErbB4 signalling via ADAM17. Finally, miR-199a, which is suppressed by STAT3, 16 directly down-regulates ErbB4 in cardiomyocytes.
We present evidence that this novel STAT3-dependent network is also impaired in dobutamine-treated PPCM patients because they b-AR agonist treatment in PPCM patients display lower cardiac STAT3, triglyceride, pyruvate and lactate content, and increased miR-199a expression.
In conclusion, while STAT3 deficiency may be causative for PPCM by impairing the cardiac microvascular system and thereby inducing a substrate and O 2 shortage, the present study shows that it may also render PPCM patients vulnerable to b 1 -AR agonist treatment ( Figure 6G ). This vulnerability is explained by deterioration of STAT3-dependent network control of glucose metabolism that eventually results in the suppression of substrate supply to cardiac mitochondria during b 1 -AR stimulation, inducing energetic deficit, oxidative stress, cardiomyocyte death, and development of irreversible HF ( Figure 6G) . Finally, these data discourage the use of dobutamine during acute HF in PPCM patients. Should they nevertheless require dobutamine, they may benefit from improving glucose uptake by perhexiline, a drug already in clinical testing 6 ( Figure 6G ).
Limitations of the study are the retrospective analysis of dobutamine treatment in PPCM patients and the use of Iso and not dobutamine in mice.
Supplementary material
Supplementary material is available at European Heart Journal online. 
